# Paediatric Cancer

## Brain

### In Development

- **SIOP Ependymoma II**: An International Multi Centre Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma
  - ependymoma@trials.bham.ac.uk
- **PNET5**: An international prospective study on clinically standard-risk medulloblastoma in children with low-risk biological profile (PNET5 MB-LR) or average-risk biological profile (PNET5 MB-SR)
  - pnet5@trials.bham.ac.uk
- **VINILO**: Phase I-II Study of Vinblastine in Combination with Nilotinib in Children, Adolescents and Young Adults with Refractory or Recurrent Low-Grade Glioma.
  - vinilo@trials.bham.ac.uk
- **INTREPID**: A phase I dose escalation study of intrathecal Etoposide as a continuous infusion investigating duration and rate of infusion in patients with leptomeningeal metastatic brain cancer
  - intrepid@trials.bham.ac.uk

## Germ Cell

### Open

- **SIOP CNS GCT II**: Prospective trial for the diagnosis and treatment of children, adolescents and young adults with intracranial germ cell tumours
  - siopcnsgctii@trials.bham.ac.uk

## Embryonic Tumour

### Open

- **HRNBL**: High risk neuroblastoma study 1 of SIOP- Europe (SIOPEN)
  - hrnbl@trials.bham.ac.uk
- **LuDO**: A phase IIa study of 177Lutetium dotatate in children with primary refractory or relapsed high risk neuroblastoma.
  - ludo@trials.bham.ac.uk
- **GD2**: A Phase I/II dose schedule finding study of CH14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma
  - gd2@trials.bham.ac.uk
- **BEACON**: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
  - beacon@trials.bham.ac.uk

### In Development

- **IMAT**: A randomised phase I/II study of intensity modulated arc therapy techniques in abdominal neuroblastoma
  - imat@trials.bham.ac.uk

## Haematology Malignancies

### Open

- **EuroNet PHL-LP1**: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin’s Lymphoma in Children and Adolescents
  - euronetphl-lp1@trials.bham.ac.uk
- **Interfant 06**: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia (LK 2006 10)
  - interfant06@trials.bham.ac.uk
- **UKALL 2011**: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011
  - ukall2011@trials.bham.ac.uk
- **Inter-B-NHL 2010**: Intergroup trial for children or adolescents with B-Cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients
  - interbnhl@trials.bham.ac.uk
In Development

NECTAR: A Phase I trial of NECTAR (Nelarabine, Etoposide and cyclophosphamide in T-ALL relapse): A joint study of TACL and POETIC
nectar@trials.bham.ac.uk

MyeChild 01: International randomised phase III clinical trial in children with acute myeloid leukaemia with an embedded dose finding study for gemtuzumab ozogamicin in combination with induction chemotherapy
Myechild01@trials.bham.ac.uk

EuroNet PHL-C2: Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents
TBA

Histioctysis

In Development

LCH IV: International collaborative treatment protocol for children and adolescents with langerhans cell histiocytosis
lchiv@trials.bham.ac.uk

Sarcoma

Open

RMS 2005: A protocol for non-metastatic rhabdomyosarcoma (STS 2006 04)
rms2005@trials.bham.ac.uk

VIT0910: International randomised phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in patients with refractory or relapsed Rhabdomyosarcoma
vit0910@trials.bham.ac.uk

EE2012: International randomised controlled trial for the treatment of newly diagnosed Ewing’s sarcoma family of tumours
ee2012@trials.bham.ac.uk

rEECur: International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
reecur@trials.bham.ac.uk
## Adult Cancer

### Bladder

**Open**

**TUXEDO**: Phase I/II feasibility study of cetuximab with 5FU and Mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer

*Contact:* tuxedo@trials.bham.ac.uk

### Breast

**Open**

**LORIS**: Can patients with newly diagnosed low-grade DCIS safely avoid surgery, without detriment to their psychological well-being and can those patients who require surgery be identified by pathological and radiological criteria?

*Contact:* loris@trials.bham.ac.uk

### In Development

**ROSCO**: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer

*Contact:* rosco@trials.bham.ac.uk

### Haematological Malignancies

**Open**

**CyCLLe**: An early phase II trial of Cyclosporin A in early adverse risk CLL

*Contact:* cyclle@trials.bham.ac.uk

**De-Iron**: A phase II study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes

*Contact:* de-iron@trials.bham.ac.uk

**ElAStic**: A phase Ib study of Eltrombopag and Azacitidine in patients with high risk myelodysplastic syndromes and related disorders

*Contact:* elastic@trials.bham.ac.uk

**HA-1**: A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHAg) HA-1 using a DNA and MVA ‘prime/boost’ regimen

*Contact:* ha1@trials.bham.ac.uk

**LenaRIC**: Phase II study of the adjunctive use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma

*Contact:* lenaric@trials.bham.ac.uk

**FIGARO**: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation

*Contact:* figaro@trials.bham.ac.uk

**MAJIC**: A phase II study of Ruxolitinib (INCB424) in patients with High Risk Polycythaemia Vera or Essential Thrombocythaemia resistant to or intolerant of standard therapy

*Contact:* majic@trials.bham.ac.uk

**RAvVA**: A Randomised Phase II Trial of 5-Azacitidine versus Vorinostat in Combination with 5-Azacitidine in patients with Newly Diagnosed, Relapsed or Refractory Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome ineligible for intensive chemotherapy

*Contact:* ravva@trials.bham.ac.uk

**ROMAZA**: Phase I trial of Romidepsin plus Azacitidine combination therapy in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for salvage chemotherapy

*Contact:* romaza@trials.bham.ac.uk

**BREVITY**: A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity

*Contact:* brevity@trials.bham.ac.uk

**IcICLLe**: Assessment of the mechanism of action of PCI-32765 in B-cell receptor pathway inhibition in CLL

*Contact:* icicle@trials.bham.ac.uk
## Viola: A Phase I Trial of Combined Azacitidine and Lenalidomide Salvage Therapy in Patients with Acute Myeloid Leukaemia who Relapse after Allogeneic Stem Cell Transplantation

viola@trials.bham.ac.uk

## Matchpoint: MANagement of Transformed CHronic myeloid leukaemia: POnatiniAp and INtensive chemotherapy: a dose-finding study

matchpoint@trials.bham.ac.uk

## TIER: A Phase I/II Study of Thiotepa, Ifosfamide, Etoposide and Rituximab for the treatment of relapsed and refractory primary central nervous system lymphoma

tier@trials.bham.ac.uk

## In Development

**CALiBRe: **Assessment of the mechanism of action of CAL-101 in B-cell receptor pathway inhibition in CLL

calibre@trials.bham.ac.uk

**RomiCar: **Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma

romicar@trials.bham.ac.uk

**PHAZAR: **A phase Ia study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with accelerated phase myeloproliferative neoplasms, myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML)

phazar@trials.bham.ac.uk

**Bubble: **Phase I B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma

bubble@trials.bham.ac.uk

**AZTEC: **A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids

Aztec@trials.bham.ac.uk

**TORCH: **A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL)

torch@trials.bham.ac.uk

## Head and Neck

### Open

**OROMOUTH: **HPV prevalence in the mouth and oropharynx of the tonsillectomy population.

oromouth@trials.bham.ac.uk

**MVA: **A Cancer Research UK Phase Ib trial to determine the safety, tolerability and immunogenicity of extended schedule vaccination with MVA-EBNA1/LMP2 in patients with Epstein Barr Virus positive nasopharyngeal carcinoma

can-crctu-edd@adf.bham.ac.uk

### In Development

**PACIFIC: **Phase Ia trial of Atu027 in Combination with Cisplatin, 5-FU and Cetuximab in Patients with Head and Neck Cancer

pacific@trials.bham.ac.uk

**CompARE: **Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

compare@trials.bham.ac.uk

## Liver

### Open

**TACE-2: **A randomised placebo-controlled, double-blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer

tace2@trials.bham.ac.uk
### In Development

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMMUNOTACE</td>
<td>A phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with Dendritic Cells pulsed with HepG2 lysate in vivo in patients with Hepatocellular Carcinoma</td>
<td><a href="mailto:immunotace@trials.bham.ac.uk">immunotace@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td>ACTICCA-1</td>
<td>Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma</td>
<td><a href="mailto:acticca-01@trials.bham.ac.uk">acticca-01@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>

### Lung

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>STOMP</td>
<td>A randomised phase II study of AZD2281 maintenance treatment in patients with chemosensitive small cell lung cancer</td>
<td><a href="mailto:stomp@trials.bham.ac.uk">stomp@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td>National Lung Matrix</td>
<td>Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer</td>
<td><a href="mailto:lungmatrix@trials.bham.ac.uk">lungmatrix@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>

### In Development

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPECIAL</td>
<td>Standard or Palliative Care In Advanced Lung cancer. Does early referral of patients with metastatic non-small cell lung cancer to UK specialist palliative care services make a difference in their quality of life or survival?</td>
<td><a href="mailto:special@trials.bham.ac.uk">special@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td>RUXSAC</td>
<td>A double blind, placebo-controlled, randomised phase II study of Pemetrexed and Cisplatin with and without Ruxolitinib in Malignant Pleural Mesothelioma</td>
<td><a href="mailto:ruxsac@trials.bham.ac.uk">ruxsac@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>

### Prostate

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADUP</td>
<td>A Phase I Clinical Trial of a replication defective type 5 adenovirus vector expressing nitroreductase and GMCSF (AdNRGM) given via transperineal, template-guided, intra-prostatic injection, followed by intravenous CB1954, in patients with locally relapsed hormone-refractory Prostate Cancer.</td>
<td><a href="mailto:adup@trials.bham.ac.uk">adup@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td>CANTATA</td>
<td>A multicentre phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy</td>
<td><a href="mailto:cantata@trials.bham.ac.uk">cantata@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>

### Renal

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAZ02</td>
<td>A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and Performance Status 2 (ECOG)</td>
<td><a href="mailto:pazo2@trials.bham.ac.uk">pazo2@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td>ADIUVO</td>
<td>Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence</td>
<td><a href="mailto:adiuvo@trials.bham.ac.uk">adiuvo@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>
### Sarcoma

**Open**

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Axi-STS</strong></td>
<td>A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas</td>
<td><a href="mailto:axi-sts@trials.bham.ac.uk">axi-sts@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td><strong>SCART</strong></td>
<td>Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi’s sarcoma (KS).</td>
<td><a href="mailto:scart@contacts.bham.ac.uk">scart@contacts.bham.ac.uk</a></td>
</tr>
</tbody>
</table>

### Skin

**Open**

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UKMCC-01</strong></td>
<td>A phase II study of pazopanib in metastatic merkel cell carcinoma</td>
<td><a href="mailto:ukmcc-01@trials.bham.ac.uk">ukmcc-01@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td><strong>SPOT</strong></td>
<td>Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments (SPOT): a feasibility study</td>
<td><a href="mailto:spot@trials.bham.ac.uk">spot@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>

### Gynaecology

**Open**

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DESKTOP III</strong></td>
<td>A randomized multicentre study to compare the efficacy of additional tumour de-bulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer</td>
<td><a href="mailto:desktopIII@trials.bham.ac.uk">desktopIII@trials.bham.ac.uk</a></td>
</tr>
<tr>
<td><strong>EPIVIN</strong></td>
<td>Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia</td>
<td><a href="mailto:epivin@trials.bham.ac.uk">epivin@trials.bham.ac.uk</a></td>
</tr>
</tbody>
</table>
**Paediatric Non-Cancer**

**Disease Prevention**

| Open | **PEP**talk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer | peptalk2@trials.bham.ac.uk |

**Adult Non-Cancer**

**Liver**

| Open | **BUTEO**: A Single arm, Two-stage, Multi-centre, Phase II clinical trial investigating the safety and activity of the use of BTT1023, a vascular adhesion protein (Vap-1) in the treatment of patients with Primary Sclerosing Cholangitis (PSC) | buteo@trials.bham.ac.uk |

| In Development | **AUTUMN**: AUtologous T-regulatory cell tracking after infUision in autoiMmuNe liver disease patients | autumn@trials.bham.ac.uk |

**Supportive Care**

| In Development | **FOAM**: Folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women | foam@trials.bham.ac.uk |